Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Chemotherapy is still one of the principal treatments for gastric cancer, but the clinical application of 5-FU is limited by drug resistance. Here, we demonstrate that ferroptosis triggered by STAT3 inhibition may provide a novel opportunity to explore a new effective therapeutic strategy for gastric cancer and chemotherapy resistance. We find that ferroptosis negative regulation (FNR) signatures are closely correlated with the progression and chemoresistance of gastric cancer. FNR associated genes (GPX4, SLC7A11, and FTH1) and STAT3 are upregulated in 5-FU resistant cells and xenografts. Further evidence demonstrates that STAT3 binds to consensus DNA response elements in the promoters of the FNR associated genes (GPX4, SLC7A11, and FTH1) and regulates their expression, thereby establishing a negative STAT3-ferroptosis regulatory axis in gastric cancer. Genetic inhibition of STAT3 activity triggers ferroptosis through lipid peroxidation and Fe2+ accumulation in gastric cancer cells. We further develop a potent and selective STAT3 inhibitor, W1131, which demonstrates significant anti-tumor effects in gastric cancer cell xenograft model, organoids model, and patient-derived xenografts (PDX) model partly by inducing ferroptosis, thus providing a new candidate compound for advanced gastric cancer. Moreover, targeting the STAT3-ferroptosis circuit promotes ferroptosis and restores sensitivity to chemotherapy. Our finding reveals that STAT3 acts as a key negative regulator of ferroptosis in gastric cancer through a multi-pronged mechanism and provides a new therapeutic strategy for advanced gastric cancer and chemotherapy resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695 · cited 17×
“Our study also reveals that down-regulation of SLC7A11 and GPX4 by STAT3 inhibition promotes intracellular lipid ROS and MDA level increment and leads to ferroptosis in gastric cancer.”
BackgroundInfluentialSmyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2239 · Cited by 4,293 · cited 1×
“Acyl-CoA synthetase long-chain family member 4 (ACSL4), a lipid metabolism enzyme required for ferroptosis, resulting in elevated lipid peroxidation and ferroptosis [27].”
BackgroundFerroptosis: molecular mechanisms and health implications
Tang, D., Chen, X., Kang, R., & Kroemer, G. (2021) · Cell Research · doi:10.1038/s41422-020-00441-1 · Cited by 4,256
Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice
Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, V. J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3064 · Cited by 3,732
Ferroptosis: process and function
Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., & Tang, D. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.158 · Cited by 3,727
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398
Broadening horizons: the role of ferroptosis in cancer
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00462-0 · Cited by 2,897
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261 · cited 1×
“Drug-protein interaction was examined in the native cellular environment basing on ligand-induced changes in protein thermal stability in CETSA assay [40,41].”
MethodFerroptosis: machinery and regulation
Chen, X., Li, J., Kang, R., Klionsky, D. J., & Tang, D. (2021) · Autophagy · doi:10.1080/15548627.2020.1810918 · Cited by 2,099
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011
Ferroptosis, a new form of cell death: opportunities and challenges in cancer
Mou, Y., Wang, J., Wu, J., He, D., Zhang, C., Duan, C., & Li, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0720-y · Cited by 1,930
Self-citationDHODH-mediated ferroptosis defence is a targetable vulnerability in cancer
Mao, C., Liu, X., Zhang, Y., Lei, G., Yan, Y., Lee, H., Koppula, P., Wu, S., Zhuang, L., Fang, B., et al. (2021) · Nature · doi:10.1038/s41586-021-03539-7 · Cited by 1,900
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., Galeas, J., Dhruv, H. D., Berens, M. E., Schreiber, S. L., et al. (2017) · Nature · doi:10.1038/nature24297 · Cited by 1,799
Kim, S. T., Cristescu, R., Bass, A. J., Kim, K.-M., Odegaard, J. I., Kim, K., Liu, X. Q., Sher, X., Jung, H., Lee, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0101-z · Cited by 1,654
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
Zhang, H., Deng, T., Liu, R., Ning, T., Yang, H., Liu, D., Zhang, Q., Lin, D., Ge, S., Bai, M., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01168-8 · Cited by 1,016
Self-citationThe chemical basis of ferroptosis
Conrad, M., & Pratt, D. A. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0408-1 · Cited by 1,002
Iron Metabolism in Ferroptosis
Chen, X., Yu, C., Kang, R., & Tang, D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.590226 · Cited by 959
Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., Wong, D. J. L., Atefi, M., Shirazi, R., Wang, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.017 · Cited by 938 · cited 2×
“Cancer cells which are resistant to conventional treatment might be particularly susceptible to ferroptosis, in terms of the current research results [9], thus the development of novel therapeutic strategies based on ferroptosis may alleviate current gastric cancer resistance.”
BackgroundProgress in the treatment of advanced gastric cancer
Song, Z., Wu, Y., Yang, J., Yang, D., & Fang, X. (2017) · Tumor Biology · doi:10.1177/1010428317714626 · Cited by 924
Koppula, P., Zhang, Y., Zhuang, L., & Gan, B. (2018) · Cancer Communications · doi:10.1186/s40880-018-0288-x · Cited by 915
Wang, T., Fahrmann, J. F., Lee, H., Li, Y.-J., Tripathi, S. C., Yue, C., Zhang, C., Lifshitz, V., Song, J., Yuan, Y., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.001 · Cited by 825
Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L. R., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609757104 · Cited by 736
Self-citationConrad, M., & Sato, H. (2012) · Amino Acids · doi:10.1007/s00726-011-0867-5 · Cited by 598
Mora, L. B., Buettner, R., Seigne, J. D., Diaz, J. I., Ahmad, N., Garcia, R., Bowman, T. L., Falcone, R., Fairclough, R., Cantor, A. B., et al. (2002) · PubMed · Cited by 597
Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) in cancer: Focusing on mitochondria
Zhong, H., & Yin, H. (2015) · Redox Biology · doi:10.1016/j.redox.2014.12.011 · Cited by 536
Management of gastric cancer in Asia: resource-stratified guidelines
Shen, L., Shan, Y.-S., Hu, H.-M., Price, T. J., Sirohi, B., Yeh, K.-H., Yang, Y.-H., Sano, T., Yang, H.-K., Zhang, X., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70436-4 · Cited by 461
Self-citationRedox imbalance in cystine/glutamate transporter-deficient mice
Sato, H., Shiiya, A., Kimata, M., Maebara, K., Tamba, M., Sakakura, Y., Makino, N., Sugiyama, F., Yagami, K.-I., Moriguchi, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506439200 · Cited by 422 · cited 1×
“Recent studies showed that inhibition of SLC7A11 or GPX4 causes lipid peroxidation and leads to ferroptosis in mammalian cells or tissues [30,35,36].”
BackgroundSTAT signaling in head and neck cancer
Song, J. I., & Grandis, J. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203483 · Cited by 374
Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer
Roh, J.-L., Kim, E. H., Jang, H. J., Park, J. Y., & Shin, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.035 · Cited by 373
A Quantitative Model of Thermal Stabilization and Destabilization of Proteins by Ligands
Cimmperman, P., Baranauskienė, L., Jachimovičiūtė, S., Jachno, J., Torresan, J., Michailovienė, V., Matulienė, J., Sereikaitė, J., Bumelis, V., & Matulis, D. (2008) · Biophysical Journal · doi:10.1529/biophysj.108.134973 · Cited by 352
Zhang, X., Yue, P., Page, B. D. G., Li, T., Zhao, W., Namanja, A. T., Paladino, D., Zhao, J., Chen, Y., Gunning, P. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121606109 · Cited by 344
Self-citationHussain, S. F., Kong, L.-Y., Jordan, J., Conrad, C., Madden, T., Fokt, I., Priebe, W., & Heimberger, A. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1243 · Cited by 314
Liu, Q., & Wang, K. (2019) · Cell Biology International · doi:10.1002/cbin.11121 · Cited by 271
Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells
Burke, W. M., Jin, X., Lin, H.-J., Huang, M., Liu, R., Reynolds, R. K., & Lin, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204990 · Cited by 269
Ferroptosis is a lysosomal cell death process
Gao, H., Bai, Y., Jia, Y., Zhao, Y., Kang, R., Tang, D., & Dai, E. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.07.078 · Cited by 244
Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01530 · Cited by 233 · cited 1×
“S3C) is similar to that of compound SI-109 [39] (Fig.”
ResultNrf2 and STAT3 Alleviates Ferroptosis-Mediated IIR-ALI by Regulating SLC7A11
Qiang, Z., Dong, H., Xia, Y., Chai, D., Hu, R., & Jiang, H. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5146982 · Cited by 212
The α6β4 integrin promotes resistance to ferroptosis
Brown, C. W., Amante, J. J., Goel, H. L., & Mercurio, A. M. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201701136 · Cited by 194
Zhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T., & Turkson, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.001 · Cited by 179
Self-citationAzwar, S., Seow, H. F., Abdullah, M., Faisal Jabar, M., & Mohtarrudin, N. (2021) · Biology · doi:10.3390/biology10090854 · Cited by 173
Wang, C., Shi, M., Ji, J., Cai, Q., Zhao, Q., Jiang, J., Liu, J., Zhang, H., Zhu, Z., & Zhang, J. (2020) · Aging · doi:10.18632/aging.103598 · Cited by 152
Zhang, X., Sun, Y., Pireddu, R., Yang, H., Urlam, M. K., Lawrence, H. R., Guida, W. C., Lawrence, N. J., & Sebti, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3175 · Cited by 148
Self-citationIdentification of a New Series of STAT3 Inhibitors by Virtual Screening
Matsuno, K., Masuda, Y., Uehara, Y., Sato, H., Muroya, A., Takahashi, O., Yokotagawa, T., Furuya, T., Okawara, T., Otsuka, M., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000273 · Cited by 146
Yang, C., Song, J., Hwang, S., Choi, J., Song, G., & Lim, W. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102144 · Cited by 135
Judd, L. M., Bredin, K., Kalantzis, A., Jenkins, B. J., Ernst, M., & Giraud, A. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.018 · Cited by 134
Fuchs, C. S., Niedzwiecki, D., Mamon, H. J., Tepper, J. E., Ye, X., Swanson, R. S., Enzinger, P. C., Haller, D. G., Dragovich, T., Alberts, S. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2130 · Cited by 133
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Oh, D.-Y., Lee, S.-H., Han, S.-W., Kim, M.-J., Kim, T.-M., Kim, T.-Y., Heo, D. S., Yuasa, M., Yanagihara, Y., & Bang, Y.-J. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.249 · Cited by 123
Bendell, J. C., Hong, D. S., Burris, H. A., Naing, A., Jones, S. F., Falchook, G., Bricmont, P., Elekes, A., Rock, E. P., & Kurzrock, R. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2480-2 · Cited by 115
Zheng, Q., Dong, H., Mo, J., Zhang, Y., Huang, J., Ouyang, S., Shi, S., Zhu, K., Qu, X., Hu, W., et al. (2020) · Theranostics · doi:10.7150/thno.49600 · Cited by 110
Self-citationOgura, M., Uchida, T., Terui, Y., Hayakawa, F., Kobayashi, Y., Taniwaki, M., Takamatsu, Y., Naoe, T., Tobinai, K., Munakata, W., et al. (2015) · Cancer Science · doi:10.1111/cas.12683 · Cited by 107
Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression
Wang, W., Guo, W., Li, L., Fu, Z., Liu, W., Gao, J., Shu, Y., Xu, Q., Sun, Y., & Gu, Y. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.024 · Cited by 91
Targeting STAT3 inhibition to reverse cisplatin resistance
Sun, C., Nie, J., Huang, J.-P., Zheng, G., & Feng, B. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109135 · Cited by 90
Yue, P., Lopez‐Tapia, F., Paladino, D., Li, Y., Chen, C., Namanja, A. T., Hilliard, T. S., Chen, Y., Tius, M. A., & Turkson, J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3558 · Cited by 80
Self-citationWiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma
Menotti, M., Ambrogio, C., Cheong, T.-C., Pighi, C., Mota, I., Cassel, S. H., Compagno, M., Wang, Q., Dall’Olio, R., Minero, V. G., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0262-9 · Cited by 76
Perspectives Regarding the Intersections between STAT3 and Oxidative Metabolism in Cancer
Chun, K., Jang, J., & Kim, D. (2020) · Cells · doi:10.3390/cells9102202 · Cited by 66
Linher‐Melville, K., & Singh, G. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.014 · Cited by 56
Manoochehri, M., Karbasi, A., Bandehpour, M., & Kazemi, B. (2013) · Pathology & Oncology Research · doi:10.1007/s12253-013-9695-0 · Cited by 48
Cited by
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Li, F.-J., Long, H.-Z., Zhou, Z.-W., Luo, H.-Y., Xu, S.-G., & Gao, L.-C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.910292 · Cited by 438
Overcoming cancer chemotherapy resistance by the induction of ferroptosis
Wang, Y., Wu, X., Ren, Z., Li, Y., Zou, W., Chen, J., & Wang, H. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100916 · Cited by 361
Self-citationRelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer
Xu, Z., Wang, X., Sun, W., Xu, F., Kou, H., Hu, W., Zhang, Y., Jiang, Q., Tang, J., & Xu, Y. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102952 · Cited by 76
Metadata
- Authors
- Ouyang, S., Li, H., Lou, L., Huang, Q., Zhang, Z., Mo, J., Li, M., Lu, J., Zhu, K., Chu, Y., Ding, W., Zhu, J., Lin, Z., Zhong, L., Wang, J., Yue, P., Turkson, J., Liu, P., Wang, Y., & Zhang, X.
- Venue
- Redox Biology
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 52
- Pages
- 102317
- ISSN
- 2213-2317 (ISSN-L)
- OpenAlex
- W4224248664
- Cited by
- 507
- References
- 64
- FWCI
- 59.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.